Search Results

You are looking at 1 - 10 of 33 items for :

  • "chronic myeloid leukaemia" x
  • All content x
Clear All
Hungarian Medical Journal
Authors: Miklós Egyed, Balázs Kollár, Péter Rajnics, Éva Karádi, and András Matolcsi

Colombat, M., Fort, M. P., Chollet, C. et al.: Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment

Restricted access
Orvosi Hetilap
Authors: Miklós Egyed, Balázs Kollár, Péter Rajnics, Éva Karádi, and András Matolcsi

Colombat, M., Fort, M. P., Chollet, C. és mtsai: Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment

Restricted access
Orvosi Hetilap
Authors: Aliz-Beáta Tunyogi, Erzsébet Lázár, István Benedek jr., Johanna Sándor-Kéri, Annamária Zsigmond, and István Benedek

References 1 Arrigoni E, Del Re M, Galimberti S, et al. Concise review: chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment. Stem Cells

Restricted access

A krónikus myeloid leukaemia tirozin-kináz-gátló kezelésének mellékhatásai és azok gyakorlati ellátása

Practical management of side effects of tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Orvosi Hetilap
Authors: Gabriella Mezei, Árpád Illés, and Péter Batár

myeloid leukemia. Leukemia 2016; 30: 48–56. 4 Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic

Open access

. 2014; 38: 1162–1164. 22 Iriyama N, Tokuhira M, Takaku T, et al. Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase

Restricted access
Orvosi Hetilap
Authors: Árpád Bátai, Péter Reményi, Marienn Réti, Anikó Barta, László Gopcsa, Lilla Lengyel, Éva Torbágyi, Zoltán Csukly, Éva Karászi, Attila Tordai, Hajnalka Andrikovics, Katalin Balassa, Szabolcs Tasnády, and Tamás Masszi

-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia. Acta Haematol., 2001, 105 (2), 64–70. 6 Janicsák, H., Masszi, T., Reményi, P., et al

Open access

361 943 951 Hehlmann, R., Hochhaus, A., Baccarani, M., et al.: Chronic myeloid leukaemia. Lancet, 2007, 370 , 342

Restricted access
Orvosi Hetilap
Authors: Judit Demeter, Anna Poros, Csaba Bödör, Laura Horváth, and Tamás Masszi

.: European Leukemia Net recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013, 122 (6), 872–884. 3 Financial protocol for the treatment of chronic

Open access

Increasing number of data suggests that locally produced histamine is involved in regulation of hematopoiesis. In this study the granulocyte/macrophage (CFU-GM) colony formation by normal murine or human bone marrow cells, leukaemic colony formation (CFU-L) by a murine leukemia cell line (WEHI 3B), and colony formation by bone marrow cells from patients with chronic myeloid leukemia (CML) have been examined. We detected mRNA and protein expression of histidine decarboxylase (HDC), the only enzyme responsible for histamine synthesis both in normal bone marrow progenitor cells and in leukaemic progenitors. The significance of in situ generated histamine was shown on colony formation by inhibitory action of aFMH (blocking HDC activity, i.e. de novo histamine formation) and by N,N-diethyl-2-{4-(phenylmethyl)phenoxy}-ethanamine-HCl (DPPE) disturbing the interference of histamine with intracellular binding sites. These data provide further confirmation of the role of histamine in development and colony formation of bone marrow derived cells.

Restricted access

N, Visser O, Ossenkoppele G, et al. Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment and survival in 3585 patienst from 1989 to 2012. Eur J Haematol. 2016; 97

Open access